Cost-Effectiveness of Percutaneous Coronary Intervention with cobalt-Chromium Everolimus Eluting Stents versus Bare Metal Stents : Results from a Patient Level meta-Analysis of Randomized Trials

Nicole Ferko,* MSC, Giuseppe Ferrante, MD, PhD, James T. Hasegawa, MPH, MBA, Tanya Schikorr, MSC, Ireena M. Soleas, MSC, John B. Hernandez, PhD, Manel Sabat e, MD, PhD, Christoph Kaiser, MD, Salvatore Brugaletta, MD, PhD, Jose Maria de la Torre Hernandez, MD, PhD, Soeren Galatius, MD, DMSC, Angel Cequier, MD, PhD, Franz Eberli, MD, Adam de Belder, MD, FRCP, Patrick W Serruys, MD, PhD, and Marco Valgimigli MD, PhD

[1]  A. Kastrati,et al.  Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis , 2015, The Lancet.

[2]  G. Stone,et al.  Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. , 2015, Journal of the American College of Cardiology.

[3]  G. Lip,et al.  Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials , 2015, BMJ : British Medical Journal.

[4]  F. Eberli,et al.  Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis , 2014, BMJ : British Medical Journal.

[5]  Andrea Benedetti,et al.  Systematic review of methods for individual patient data meta- analysis with binary outcomes , 2014, BMC Medical Research Methodology.

[6]  Mario Fusaro,et al.  Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis , 2013, BMJ.

[7]  C. Combescure,et al.  The favorable price evolution between bare metal stents and drug eluting stents increases the cost effectiveness of drug eluting stents. , 2013, International journal of cardiology.

[8]  Vladimir Dzavik,et al.  Medical Therapy v. PCI in Stable Coronary Artery Disease , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[9]  G. Stone,et al.  Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial). , 2012, The American journal of cardiology.

[10]  A. Kirtane,et al.  Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trials , 2012, BMJ : British Medical Journal.

[11]  A. Kansal,et al.  Economic modeling of new stent platforms to evaluate cost effectiveness: analysis of the TAXUS Liberté versus TAXUS express stents. , 2012, Journal of interventional cardiology.

[12]  G. Stone,et al.  Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.

[13]  Laura Mauri,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.

[14]  R. Riley,et al.  Meta-analysis of individual participant data: rationale, conduct, and reporting , 2010, BMJ : British Medical Journal.

[15]  J. Hutton,et al.  Cost-effectiveness of the Endeavor stent in de novo native coronary artery lesions updated with contemporary data. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[16]  Jiannong Liu,et al.  Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[17]  M. Briel,et al.  Cost-effectiveness of drug-eluting stents in a US Medicare setting:a cost-utility analysis with 3-year clinical follow-up data. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[18]  S. Windecker,et al.  The drug-eluting stent saga. , 2009, Circulation.

[19]  A. Whitehead,et al.  Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials , 2009, Clinical trials.

[20]  Laura Mauri,et al.  Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. , 2008, Journal of the American College of Cardiology.

[21]  M. Pfisterer,et al.  Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-month analysis , 2007, The Lancet.

[22]  Ameet Bakhai,et al.  Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses: Results From the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) Trial , 2004, Circulation.

[23]  Andrew Briggs,et al.  Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. , 2004, Health economics.

[24]  A Briggs,et al.  Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. , 1994, Health economics.

[25]  P. Serruys,et al.  Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted Fro , 2014, JACC. Cardiovascular interventions.

[26]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[27]  W. Little,et al.  Cost-Effectiveness of Drug-Eluting Stents Versus Bare Metal Stents in Clinical Practice , 2011 .

[28]  I. Durand-zaleski,et al.  Cost effectiveness of sirolimus-eluting stents compared with bare metal stents in acute myocardial infarction: insights from the TYPHOON trial. , 2009, Applied health economics and health policy.

[29]  Lynn A. Sleeper,et al.  Cost-Effectiveness of Percutaneous Coronary Intervention With Drug Eluting Stents Versus Bypass Surgery for Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease: Results From the FREEDOM Trial , 2013, Circulation.